DENVER, Colo., September 4, 2019- (24/7MarketNews via COMTEX) Venture Market News for September 4, 2019.
Aleafia Health Expands Outdoor Cannabis Facility by Additional 60 Acres with Property Acquisition
- New property cost $1.2 million and is directly adjacent to current Port Perry Outdoor Grow facility
- Company subsidiary, Emblem, also closes sale of unused Brant, Ont. property for $8.2 million in net cash
TORONTO, Sept. 04, 2019 (GLOBE NEWSWIRE) — Aleafia Health Inc. (TSX: ALEF, OTC: ALEAF, FRA: ARAH) (“Aleafia Health” or the “Company”)’s wholly owned subsidiary, Aleafia Farms Inc., has acquired the farmland directly adjacent to its Port Perry Outdoor Grow facility. The purchase will allow the Company to commence its Outdoor Grow Phase II expansion, adding an additional 60 acres of cannabis cultivation area, for a total of 86 acres. The transaction closed on September 3, 2019, with a cash purchase price of $1.2 million.
Genentech to Present Pivotal Data for Satralizumab in Neuromyelitis Optica Spectrum Disorder and Six-year Ocrevus (Ocrelizumab) Data in Multiple Sclerosis at ECTRIMS
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data across its neuroscience portfolio will be presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from September 11-13 in Stockholm. Presentations include complete Phase III results from the SAkuraStar study investigating satralizumab for the treatment of neuromyelitis optica spectrum disorder (NMOSD), and new multiple sclerosis (MS) research, which provides insights into disease progression, including data from Ocrevus® (ocrelizumab) trials that advance understanding of neurofilament light chain (NfL) levels as a potential biomarker for predicting disability outcomes. Additionally, longer-term data of more than six years to be presented continue to show consistent safety and efficacy outcomes for patients treated with Ocrevus earlier.
ALLTEMP, INC. (OTCPK:LTMP) Announces the Appointment of Marston Webb as International Public and Investor Relations Consultant
NEW YORK, NY / ACCESSWIRE / September 4, 2019 / Alltemp, Inc., (OTC PINK:LTMP), has announced the engagement of Marston Webb International of New York effective immediately. The agency, which will assist the company in managing all aspects of its public and investor relations along with market awareness programs, brings to Alltemp, Inc. more than 30 years of relevant industry experience.
CytoDyn Files an IND and a Phase 2 Protocol with the FDA for the Treatment of NASH with Leronlimab
VANCOUVER, Washington, Sept. 04, 2019 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the filing of an IND and a Phase 2 clinical trial protocol with the FDA for the treatment of non-alcoholic steatohepatitis (NASH). Based on published reports of the involvement of CCR5 in the pathogenesis of NASH, and following the Company’s recent announcement of positive preclinical data, the Phase 2 trial is designed to test whether leronlimab may control the devastating liver fibrosis associated with NASH.
Medicine Man Technologies to Bolster Retail Distribution Channels with Planned Acquisition of Colorado Harvest Company
– Colorado Harvest Company operates three retail centers in the Denver Metro area and is the Company’s ninth proposed acquisition in 2019
– Company will benefit from added retail scale and cross-selling opportunities given its current strategy to acquire a fast-growing portfolio of companies and brands
– Industry pioneers Tim Cullen and Ralph Morgan, Co-Founders of Colorado Harvest Company, bring a wealth of retail experience and their proprietary, all-natural strains to the Company
DENVER, Sept. 4, 2019 /PRNewswire/ — Medicine Man Technologies, Inc. (OTCQX: MDCL) (“Medicine Man Technologies” or the “Company”), announced today that it has entered into a binding term sheet to acquire Colorado Harvest Company (“Colorado Harvest”), an operator of two leading cannabis dispensaries in Denver and one in nearby Aurora.
Fiore Gold Delivers Back to Back Quarters of Record Gold Production and Improving Liquidity
(TSXV:F) (OTCQB:FIOGF) (“Fiore” or the “Company”) is pleased to announce that its financial statements and managements discussion and analysis for the third fiscal quarter (Q3 2019) ended ebsite at www.fioregold.com.
Khiron Initiates Construction of Cultivation and Processing Facility in Uruguay, Expanding Multi-Jurisdiction and Export Capacity
- Facility in Juan Lacaze includes GAP-compliant 8,000 m2 (86,111 sq.ft) cultivation area and a GMP-compliant 1,800 m2 (19,375 sq.ft) processing plant, with a production capacity of 17 tons per year
- Increases Khiron’s total production capacity and strengthens ability to export and supply cannabis across the Mercosur trading bloc, with access to Brazil and Europe
- Medical cannabis markets in Brazil and Europe are expected to be respectively worth $144.3 billion USD and €115.7 Billion by 2028 (Source: Prohibition Partners)
- Construction scheduled for completion in mid Q3 2020
TORONTO, Sept. 4, 2019 /PRNewswire/ – Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, announced today that it has commenced construction of a 9,800 m2 (105,486 sq.ft) cultivation and processing facility in Juan Lacaze, Uruguay. With a production capacity of 17 tons per year, the Company’s investment in this state-of-the-art facility represents a significant increase in Khiron’s total production capacity, strengthening its ability to export and supply cannabis to key international markets, including Brazil and Europe. Construction is underway and is scheduled for completion in mid Q3 2020.
Connect with 24/7 Market News on social media:
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN provides comprehensive corporate communications resources and tools to engage the investment community.
24/7 Market News (24/7MN) is a third party publisher and news dissemination service provider that produces regular sponsored and non-sponsored reports, articles, stock market blogs, and newsletters covering equities listed on the NYSE, NASDAQ and micro-cap exchanges. 24/7MN holds no investment licenses and is NOT a financial advisory firm, investment adviser, analyst, or broker-dealer and does not undertake any activities that would require such registration. 24/7MN’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.
The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and based on publicly available information which is believed to be reliable. 24/7MN owns LTMP shares that it will sell. 24/7MN makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. 24/7MN and/or its affiliates are not responsible for any gains or losses that result from the opinions expressed and are not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.
For further information on 24/7 Market News, please go to www.247marketnews.com
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan,” or “planned,” “will,” or “should,” “expected,” “anticipates,” “draft,” “eventually,” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 24/7MN undertakes no obligation to update such statements
24/7 Market News